J&J’s $5bn projects have much to prove
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Asco 2022 – Carvykti casts a long shadow
Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.
Another strike for biotech: China
Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
Go or no go? Pdufa resolutions eyed for J&J and Amryt
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
